According to a new report published by K D Market Insights, titled, “Aptamers Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global aptamers market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The increasing demand for specific and efficient targeting molecules in various applications, such as therapeutics, diagnostics, and research. Aptamers, being highly versatile and adaptable, offer advantages over traditional antibodies and small molecule drugs. Which are the major factors augmenting the growth of the global aptamers market.
The rising awareness of the advantages of aptamers over antibodies fuels market growth. Aptamers offer unique advantages such as high specificity, low immunogenicity, and ease of synthesis, making them attractive for various applications in diagnostics, therapeutics, and research are further expected to create ample growth opportunities for the global aptamers market during the forecast period i.e., 2023-2032. Moreover, advancements in the field of aptamer development technologies has propelled market expansion. The rising prevalence of chronic diseases and the need for accurate diagnostic tools drive the demand for aptamer-based diagnostics, is expected to contribute towards the market growth during the period.
The North America region accounted for the largest share in the global aptamers market in 2022. The region is further projected to continue dominating in the market and also register the highest CAGR in the market during the forecast period. This can be attributed to the availability of funds to support research and development of innovative technologies, the presence of prominent market players, and the increasing collaborations among companies.
According to type, The DNA-based aptamers segment accounted for the largest market share in the aptamers market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
The global aptamers market is segmented into type, application, technology, end user and region. Based on type, the market is bifurcated into nucleic acid aptamers, peptide aptamers. Based on application, it is classified into diagnostics, therapeutics, research & development, others. Based on technology, it is classified into SELEX, x-aptamers, maras technique, others. Based on end user, it is classified into pharmaceutical & biotechnology companies, academic & government research institutes, CROs (contract research organizations), others.
Related Reports
https://www.kdmarketinsights.com/reports/pharmaceuticals-lipids-market/7390
https://www.kdmarketinsights.com/reports/pharmaceutical-excipients-market/7389
https://www.kdmarketinsights.com/reports/medical-hyperspectral-imaging-market/7388
https://www.kdmarketinsights.com/reports/human-recombinant-insulin-market/7387
The global aptamers market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).
Key Insights of Aptamers Market
- On the basis of type, The DNA-based aptamers segment accounted for the largest market share in the aptamers market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
- On the basis of region, North America accounted for the largest share in the global aptamers market in 2022. The region is further projected to continue dominating in the market during the forecast period.
- On the basis of region, Asia-Pacific is estimated to account for the second largest share in the market during the forecast period.
Some of the major aptamers market companies profiled in the report include Aptamer Sciences Inc., Somalogic Inc., Base Pair Biotechnologies Inc., Ophthotech Corporation, Am Biotechnologies, Aptamer Solutions Ltd., Aptus Biotech S.L., Neoventures Biotechnology Inc., Aptagen LLC, Trilink Biotechnologies Inc., Vivonics Inc., and Noxxon Pharma.
